2004-2006南京地区抗肿瘤药物应用分析

Analysis of antineoplastic drug uses in urban hospitals of Nanjing during 2004-2006

目的:评价南京地区2004-2006年抗肿瘤药物应用情况。方法:采用金额排序法和限定日剂量数排序法(DDDs排序法),对南京地区样本医院2004-2006年抗肿瘤药物用药金额、限定日剂量数进行统计分析。结果:南京市抗肿瘤药物用药总金额大幅增加,2006年已达到1.97亿元;金额排名中,铂类、抗肿瘤激素类和单抗类等综合大类居首位,抗肿瘤植物药居第2位;抗肿瘤西药中,紫杉醇、奥沙利铂、吉西他滨和紫杉特尔交替出现在金额排名前4位;他莫昔芬始终居于DDDs排序中榜首;利妥昔单抗的金额排序和DDDs排序同步增长,来曲唑的DDDs排序明显提高;抗肿瘤中药方面,金额排序与DDDs排序同步性较好,华蟾素的排序逐年上升,而康莱特的排序逐年下降。结论:南京市抗肿瘤药物用药呈现快速增长趋势;临床对抗肿瘤药物的选择逐渐由传统的抗肿瘤药物和中药转向高效、低毒、具有靶向作用的新型抗肿瘤药物。

Objective： To analyze and evaluate during 2004 - 2006. Methods： Consumption of antine suits： Up to 2006, the costs of antineoplastic drugs in antineoplastic drug uses in urban hospitals of Nanjing oplastic Nanjing drugs was analyzed by sum and DDDs ranking. Rewere close to two hundred million Yuan. Annual increasing rate of cost were 17.98% in 2005 and 23.42% in 2006, respectively. The consumption sum of platin derivatives, hormones, monoclonal antibodies and other genus ranked the first place, and the sum of anti-cancer vegetable drugs ranked the second place. The increasing rate of antineoplastic traditional Chinese medicines stepped down. Paclitaxel, oxaliplatin, gemcitabine and taxotere were listing within cost top 4, and tamoxifen was always listing in top 1 of DDDs. Both DDDs and cost position of rituximab and letrozole went forward markedly. Rank of cost in antineoplastic traditional Chinese medicines was nearly coincident with rank of DDDs; however, its cost top varied annually. Conclusions ： The general development of antineoplastic drug uses shows a rapidly upward trend in Nanjing city; the new monoantibodies and gene drugs were increasingly used. The direction is towards the use of antineoplastic drugs with high efficiency and low toxicity